摘要
目的:利用Meta分析方法,评价拉米夫定联合干扰素(LAM+IFN)与单独应用拉米夫定(LAM)治疗慢性乙型肝炎(CHB)患者的疗效差异。方法:检索相关文献,对符合纳入标准的10项随机对照研究,采用固定和随机效应模型进行Meta分析,共包括986例HBeAg阳性的慢性乙型肝炎患者。结果:拉米夫定联合干扰素组患者治疗12月,血清ALT复常率、血清HBV-DNA转阴率、血清HBeAg转阴率,均优于单用拉米夫定组,其差异有统计学意义[OR(95%CI)分别为1.74(1.28,2.34)、2.11(1.49,3.00)、3.66(1.87,7.20)]。结论:HBeAg阳性患者应用拉米夫定联合干扰素的治疗方案优于LAM单药疗法。
Objective：To compare lamivudine monotherapy versus lamivudine（LAM） combined with interferon（IFN） for treating chronic hepatitis B（CHB）patients with Meta-analysis.Methods：Related literatures were searched using computer,fixed and random effect models were applied to finish the Meta analysis for the 10 randomized control studies which conformed to the included criterion involving 986 patients were identified.Results：As the Meta-analysis showed,the therapeutic effect of lamivudine combined with interferon was better than that of lamivudine in aspects of improving the negative rate of serum ALT（OR=1.74,95%CI 1.28 to 2.34）,the negative rate of serum HBV-DNA（OR=2.11,95%CI 1.49 to 3.00）,the negative rate of serum HBeAg（OR=3.66,95%CI 1.87 to 7.20）.Conclusion：LAM＋IFN combination therapy are more effective than LAM monotherapy for HBeAg positive chronic hepatitis B.
出处
《江苏预防医学》
CAS
2011年第4期38-41,共4页
Jiangsu Journal of Preventive Medicine
基金
国家科技重大专项(2009ZX10004-904)
